BioSpace News Archive

Genetic Technologies Limited confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.

Centene Corporation (NYSE: CNC) today will host its investor day virtually and outline its 2022 financial guidance as well as provide details of its Value Creation Plan, designed to deliver enhanced earnings growth and create long-term shareholder value.

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), presented clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADC).

Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, applauds the U.S. House of Representatives for its decision to pass H.R. 3537, the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).

The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 9, 2021, approved the fiscal year 2022 third quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year.

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are defined as medications that have been developed to lower cholesterol levels.

Pomalidomide is a cancer medicine used in the treatment of multiple myeloma (a cancer of the bone marrow). It is also used in combination with bortezomib (i.e. cancer medicine) and dexamethasone (an anti-inflammatory medicine) in geriatric patients who have received at least one treatment including lenalidomide.

The sinusitis drugs market has been expected to experience significant growth opportunities in the forthcoming years.

MediciNova, Inc. and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND.

Journey Medical Corporation announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.